AstraZeneca says detained China head has lawyer

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...
Guidance: For fiscal year 2024, AstraZeneca forecasts total revenue and core EPS to increase by a high-teens percentage, ...
Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...
AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl ...